FDA’s CDER announces updated guidance agenda for 2025
Regulatory NewsJoanne S. Eglovitch
Biologics License Application (BLA)BsUFACDERChemistry, Manufacturing and Controls (CMC)CompoundingGenericsGMPGuidanceManufacturingOver the counter drugs (OTCs)PharmaceuticalsPostmarketing clinical follow up (PMCF)Product developmentQuality Assurance and ControlRegulatory harmonizationRegulatory Intelligence/PolicyUnited States